Abstract
Kawasaki disease (KD) is an acute febrile disorder characterized by systemic vasculitis primarily occurring in coronary arteries. Matrix metalloproteinases (MMPs) have been considered to play pathophysiologic roles in the development of coronary artery lesions (CALs); therefore, an evaluation of the genetic contributions of the MMP genes to the development of CALs in KD patients would be beneficial for the prediction of CAL formation. We focused on the known functional single nucleotide polymorphisms (SNPs) in the MMP genes (MMP-2-735C>T, MMP-3-1612 5A/6A, MMP-9-1562C>T, MMP-12-82A>G, and MMP-13-77A>G) and performed the association study between these SNPs and CAL formation in KD. The study population consisted of 44 KD patients with CALs and 92 without CALs and 175 healthy controls. As a result, allele and genotype frequencies of MMP-13-77A>G showed significant differences between KD patients with CALs and without CALs (p = 0.00989 and p = 0.00551, respectively). The estimated frequencies of the G-C haplotype in the MMP-13 gene promoter were significantly lower in KD patients with CALs than in those without CALs. There was no association between other MMP genes and CAL formation. In conclusion, the genetic evaluation by association study demonstrated that the MMP-13 gene, at least in part, contributed to the development of CALs in KD.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- CALs:
-
coronary artery lesions
- IVIG:
-
i.v. immunoglobulin
- KD:
-
Kawasaki disease
- MMP:
-
matrix metalloproteinase
- TIMP2:
-
tissue inhibitor of metalloproteinases 2
References
Durongpisitkul K, Gururaj VJ, Park JM, Martin CF 1995 The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96: 1057–1061
Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T 2004 Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 144: 496–499
Burns JC, Glode MP 2004 Kawasaki syndrome. Lancet 364: 533–544
Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, Maruyama I, Miyata K 1998 Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 44: 596–599
Ohno T, Igarashi H, Inoue K, Akazawa K, Joho K, Hara T 2000 Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 159: 424–429
Ohno T, Yuge T, Kariyazono H, Igarashi H, Joh-o K, Kinugawa N, Kusuhara K, Hara T 2002 Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 161: 105–111
Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, Sekine I 2001 Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 125: 340–344
Kariyazono H, Ohno T, Khajoee V, Ihara K, Kusuhara K, Kinukawa N, Mizuno Y, Hara T 2004 Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 56: 953–959
Breunis WB, Biezeveld MH, Geissler J, Ottenkamp J, Kuipers IM, Lam J, Hutchinson A, Welch R, Chanock SJ, Kuijpers TW 2006 Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum 54: 1588–1594
Thornton S 2006 Contribution of angiogenic genes to the complex genetic trait underlying Kawasaki disease. Arthritis Rheum 54: 1361–1365
Furuno K, Takada H, Yamamoto K, Ikeda K, Ohno T, Khajoee V, Mizuno Y, Hara T 2007 Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease. J Pediatr 151: 155–160
Park JA, Shin KS, Kim YW 2005 Polymorphism of matrix metalloproteinase-3 promoter gene as a risk factor for coronary artery lesions in Kawasaki disease. J Korean Med Sci 20: 607–611
Ye S 2006 Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 69: 636–645
Ogata T, Shibamura H, Tromp G, Sinha M, Goddard KA, Sakalihasan N, Limet R, MacKean GL, Arthur C, Sueda T, Land S, Kuivaniemi H 2005 Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg 41: 1036–1042
Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D 2004 Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64: 7622–7628
Akagi T, Rose V, Benson LN, Newman A, Freedom RM 1992 Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr 121: 689–694
Wang Y, Fang S, Wei L, Wang R, Jin X, Wen D, Li Y, Guo W, Wang N, Zhang J 2005 No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer 49: 155–161
Lewontin RC 1995 The detection of linkage disequilibrium in molecular sequence data. Genetics 140: 377–388
Sternlicht MD, Werb Z 2001 How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463–516
Woessner JF Jr 1991 Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145–2154
Knox JB, Sukhova GK, Whittemore AD, Libby P 1997 Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 95: 205–212
Stetler-Stevenson WG 1996 Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148: 1345–1350
Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, Sasaki N, Asano H, Kyo S, Yokote Y 2001 Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 104: 860–863
Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH 2003 Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 23: 576–581
Baker AH, Edwards DR, Murphy G 2002 Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115: 3719–3727
Karagiannis ED, Popel AS 2004 A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. J Biol Chem 279: 39105–39114
Yoon S, Kuivaniemi H, Gatalica Z, Olson JM, Buttice G, Ye S, Norris BA, Malcom GT, Strong JP, Tromp G 2002 MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black males. Matrix Biol 21: 487–498
Mao D, Lee JK, VanVickle SJ, Thompson RW 1999 Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun 261: 904–910
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by a Grant-in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Rights and permissions
About this article
Cite this article
Ikeda, K., Ihara, K., Yamaguchi, K. et al. Genetic Analysis of MMP Gene Polymorphisms in Patients With Kawasaki Disease. Pediatr Res 63, 182–185 (2008). https://doi.org/10.1203/PDR.0b013e31815ef224
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/PDR.0b013e31815ef224
This article is cited by
-
Immunogenetics of Kawasaki disease
Clinical Reviews in Allergy & Immunology (2020)
-
Ascending Aorta Elastography After Kawasaki Disease Compared to Systemic Hypertension
Pediatric Cardiology (2015)
-
Transcriptional regulation by infliximab therapy in kawasaki disease patients with immunoglobulin resistance
Pediatric Research (2014)
-
A functional polymorphism, rs28493229, in ITPKC and risk of Kawasaki disease: an integrated meta-analysis
Molecular Biology Reports (2012)
-
Genetic polymorphisms in Kawasaki disease
Acta Pharmacologica Sinica (2011)
